Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$113.09 USD

113.09
11,127,844

-1.64 (-1.43%)

Updated Sep 26, 2024 04:00 PM ET

After-Market: $113.01 -0.08 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Nalak Das headshot

5 Dow Stocks Poised to Beat on Earnings This Month

Despite severe market volatility, the Dow is still in positive territory with a gain of 15.9% year to date. This is an excellent performance after a disappointing 2018.

Merck (MRK) Gains But Lags Market: What You Should Know

Merck (MRK) closed at $85.04 in the latest trading session, marking a +0.41% move from the prior day.

J&J (JNJ) Beats on Q3 Earnings as Sales Rise, Ups 2019 View

J&J (JNJ) comes up with encouraging third-quarter 2019 results.

Why Merck (MRK) is Poised to Beat Earnings Estimates Again

Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Seattle Genetics Up More Than 20% in 3 Months: Here's Why

Seattle Genetics' (SGEN) only marketed product, Adcetris, has been performing well since its launch. The company's established pipeline candidates are also progressing well.

4 Stocks From Highest Job-Creating Sectors in September

Apart from the decent number of new jobs, the unemployment rate in the United States dropped 0.2 percentage points to hit a five-decade low of 3.5% last month.

Top Ranked Growth Stocks to Buy for October 10th

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, October 10th

J&J Ordered by Philadelphia Jury to Pay $8B in Risperdal Case

Philadelphia jury orders J&J (JNJ) to pay punitive damages of $8 billion to a man who claims that the use of Risperdal caused him to develop breasts.

Merck (MRK) Stock Moves -1.33%: What You Should Know

Merck (MRK) closed the most recent trading day at $83.27, moving -1.33% from the previous trading session.

Verastem's (VSTM) Copiktra Gets Orphan Drug Designation

Verastem's (VSTM) Copiktra gets orphan drug designation from the FDA for use in the treatment of T-Cell lymphoma.

The Zacks Analyst Blog Highlights: General Dynamics, Merck, Progressive, ServiceNow, and Emerson

The Zacks Analyst Blog Highlights: General Dynamics, Merck, Progressive, ServiceNow, and Emerson

The Zacks Analyst Blog Highlights: J&J, AstraZeneca, Roche, Glaxo and Merck

The Zacks Analyst Blog Highlights: J&J, AstraZeneca, Roche, Glaxo and Merck

Novo Nordisk Focuses on Pipeline Development Amid Competition

Novo Nordisk (NVO) has a strong presence in the Diabetes care market and focuses on the development of its pipeline amid competition.

Mark Vickery headshot

Top Analyst Reports for General Dynamics, Merck & Progressive

Today's Research Daily features new research reports on 16 major stocks, including General Dynamics (GD), Merck & Co. (MRK) and Progressive (PGR).

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's Opioid Settlement, FDA Updates for AZN, GSK, MRK, RHHBY

J&J (JNJ) settles with two Ohio plaintiffs for $10 million. FDA updates for AstraZeneca (AZN), Merck (MRK) and others and ESMO presentations by big pharma companies in focus.

Gilead's Descovy HIV Regimen Gets FDA Nod for Label Expansion

Gilead (GILD) obtains FDA approval for HIV treatment Descovy as a prevention option.

Merck's Pediatric Filings for Dificid Get FDA's Priority Review

The FDA accepts and grants a priority review to Merck's (MRK) two filings for pediatric approvals of antibacterial medicine Dificid for Clostridium infections. The verdict will be out on Jan 24, 2020.

Why Merck (MRK) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

AstraZeneca's Triple-Combo COPD Inhaler Gets CRL From FDA

AstraZeneca (AZN) gets CRL from the FDA for PT010, its triple-combo inhaler to treat COPD.

Merck Sees Hammer Chart Pattern: Time to Buy?

Merck has been struggling lately, but the selling pressure may be coming to an end soon.

Merck (MRK) Stock Moves -0.68%: What You Should Know

Merck (MRK) closed the most recent trading day at $83.61, moving -0.68% from the previous trading session.

Immunomedics (IMMU) Reports Interim Urothelial Cancer Data

Immunomedics (IMMU) presents interim data on sacituzumab govitecan in patients with metastatic urothelial cancer. The company also inks two deals.

Seattle Genetics Up on Positive Data From Bladder Cancer Study

Seattle Genetics (SGEN) and Astellas' enfortumab vedotin in combination with Merck's Keytruda proves safety in a phase I study as a first-line treatment for advanced bladder cancer. Shares up.

AstraZeneca/Merck's Lynparza Positive in Prostate Cancer Study

AstraZeneca's (AZN) Lynparza doubled the time without radiographic disease progression in a study evaluating in an advanced prostate cancer patient population.

Glaxo's Zejula Betters PFS in First-Line Ovarian Cancer Study

Glaxo's (GSK) phase III study evaluating Zejula as a first-line maintenance therapy in patients with ovarian cancer significantly reduces risk of disease progression or death by 38%.